Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Related Articles Tesamorelin: Clinical Data for Visceral Fat Reduction Phase III trial data showing 15-18% visceral fat reduction and the FDA approval rationale for Egrifta
As a stable gastric pentadecapeptide, it has been widely studied as a tissue repair research peptide in structured experimental models evaluating extracellular matrix interaction and regenerative pathway research peptide mechanisms
The loading phase typically uses 2-2.5mg twice weekly for 4-6 weeks, totaling 4-5mg per week
Front Med (Lausanne)
Avoid layering peptides with high-strength AHAs or BHAs, strong Vitamin C, retinoids, and low-pH exfoliants, as they may reduce peptide activity and could cause irritation in some cases.
This product is intended for laboratory handling only by qualified research personnel
US$ 22.00
US$ 23.84
US$ 28.36
US$ 23.89
US$ 25.26
